51 F
New York
Tuesday, April 20, 2021

Relay Therapeutics [NASDAQ: RLAY] Signs A Collaborative Contract With Genetech For Development Of RLY-1971

Must read

IAA [NYSE: IAA] Announces Expansion of Delivery Services in the UK

IAA, Inc. disclosed that its UK-based business unit has decided to expand its vehicle delivery services for its buyers. This expansion decision has...

ICON [NASDAQ: ICLR] Secures Multiple Categories in 2021 CRO Leadership Awards

ICON Public Limited Company has disclosed that it has won multiple categories in the annual CRO Leadership Awards. This is another greatest achievement...

Equinox Announces Sale of Pilar Gold Mine

Equinox Gold Corp. revealed Monday that it has decided to sell its Pilar Gold Mine in Brazil to Pilar Gold Inc. The firm...

OpGen [NASDAQ: OPGN] Announces Strategic Collaboration New York State Department of Health

OpGen, Inc. revealed that it has entered into a strategic collaboration deal with the New York State Department of Health. The focus of...

Relay Therapeutics [NASDAQ: RLAY] revealed that the company inked a contract with Genetech. Both the companies agreed on the development and commercialization of RLY-1971. The drug is a strong inhibitor of SHP2. The drug is a possible pillar to serve in combination therapy to treat various tumors.

Genetech will take charge of the development of RLY-1971 with the possibility of expanding the drug into multiple combination studies. According to the terms of the worldwide license and collaboration agreement, Relay will receive a $75 million payment. The company is further eligible to receive $25M in additional payment. Relay has an option of a 50/50 profit/cost-share on the drug. The company will be eligible to receive a 50% profit from U.S sales. It will also receive $410M in additional payment and royalties on net sales if it opts for it.

If Relay chooses otherwise, the company will be eligible to obtain $695M in additional development, commercialization, and royalties on net sales. Relay still holds the right to combine with it’s FGFR2 and PI3Kα programs.

More articles

Latest article

Why Mer Telemanagement [NASDAQ: MTSL] Skyrocketed on Friday?

Shares of Mer Telemanagement Solutions Ltd skyrocketed during the trading session of Friday. The strong performance of the firm has indicated the positive...

Largo Resources Gets Approval for Listing on Nasdaq Stock Exchange

Largo Resources disclosed that it has finally obtained authorization from Nasdaq Stock Market LLC. As per the approval, the firm will now eligible to...

Aurora Mobile [NASDAQ: JG] Inks Agreement with Wanda Film

Aurora Mobile Limited disclosed Thursday that it has inked an agreement with Wanda Film Holding Co Ltd. Since its inception, Aurora Mobile has...

Brady [NYSE: BRC] Commence Tender Offer to Buy Nordic ID Oyj

Brady Corporation has inked an agreement with Nordic ID for its acquisition. The firm has commenced the tender offering to buy all the...

Cinedigm [NASDAQ: CIDM] Achieve Record Subscription and Ad-Supported User Growth Milestones

Shares of Cinedigm Corp. skyrocketed 19.30% after the firm reported the update about the subscription. The firm has achieved the best ever achievement...

Aurora Mobile [NASDAQ: JG] Signs Partnership Agreement with Yivi

Aurora Mobile Limited revealed that it has inked a collaboration deal with Hangzhou Yivi Intelligent Technology Co., LTD. (Yivi). Yivi and Aurora both...

Total [NYSE: TOT] Join Forces with Siemens Energy to Reduce LNG Related Emissions

Total SE has joined forces with Siemens Energy to explore the solution for the reduction of CO2 emissions. The firms have inked a...

Kaixin [NASDAQ: KXIN] Signs Cooperation Agreement with Jingdong

Kaixin Auto Holdings declared Monday that it has inked a deal with Jingdong Century Trade Limited. The agreement is the collaboration agreement between...